FY2025 Earnings Forecast for ABVX Issued By Lifesci Capital

ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) - Equities research analysts at Lifesci Capital lowered their FY2025 earnings per share (EPS) estimates for ABIVAX Société Anonyme in a research note issued to investors on Wednesday, June 4th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings of ($3.68) per share for the year, down from their prior forecast of ($3.14). The consensus estimate for ABIVAX Société Anonyme's current full-year earnings is ($2.83) per share.

A number of other analysts have also recently weighed in on the stock. JMP Securities restated a "market outperform" rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Wednesday, April 30th. Morgan Stanley reiterated an "equal weight" rating and set a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th.

ABIVAX Société Anonyme Price Performance

ABIVAX Société Anonyme stock traded down $0.40 during midday trading on Monday, hitting $7.02. The company's stock had a trading volume of 97,905 shares, compared to its average volume of 150,416. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $14.43. The stock's 50-day moving average price is $6.47 and its 200-day moving average price is $6.87.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Woodline Partners LP raised its holdings in shares of ABIVAX Société Anonyme by 319.5% during the first quarter. Woodline Partners LP now owns 201,924 shares of the company's stock valued at $1,262,000 after acquiring an additional 153,788 shares during the period. Octagon Capital Advisors LP purchased a new position in ABIVAX Société Anonyme during the 1st quarter worth approximately $7,688,000. Millennium Management LLC raised its stake in ABIVAX Société Anonyme by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company's stock valued at $6,171,000 after purchasing an additional 56,235 shares during the period. Allostery Investments LP lifted its holdings in shares of ABIVAX Société Anonyme by 86.0% in the first quarter. Allostery Investments LP now owns 1,099,654 shares of the company's stock valued at $6,873,000 after purchasing an additional 508,401 shares in the last quarter. Finally, ADAR1 Capital Management LLC lifted its holdings in shares of ABIVAX Société Anonyme by 46.0% in the first quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company's stock valued at $13,813,000 after purchasing an additional 696,626 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.